TREATMENT OPTIONS IN ONCOLOGY:@0.084848:0.038601:0.493541:0.038601:0.493541:0.019343:0.084848:0.019343:0.010019:0.014276:0.012606:0.015487:0.010019:0.021613:0.012606:0.017404:0.010019:0.006515:0.020438:0.013923:0.010019:0.005315:0.020438:0.017404:0.011712:0.006515:0.005315:0.017404:0.006515:0.020438:0.017404:0.019121:0.020438:0.010866:0.020438:0.020508:0.013923
28:@0.023705:0.038809:0.044778:0.038809:0.044778:0.019212:0.023705:0.019212:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.084848:0.970015:0.320957:0.970015:0.320957:0.956010:0.084848:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
Radium-223 dichloride, an alpha-emitting :@0.084848:0.861987:0.481076:0.861987:0.481076:0.846231:0.084848:0.846231:0.011680:0.013143:0.013181:0.003848:0.011699:0.018049:0.006388:0.010660:0.010660:0.010660:0.006793:0.013181:0.003848:0.012450:0.011738:0.003848:0.012604:0.005792:0.003848:0.013181:0.012508:0.005330:0.006773:0.013143:0.011738:0.006781:0.013143:0.003848:0.013123:0.011738:0.013143:0.006388:0.012508:0.018049:0.003848:0.006523:0.006523:0.003848:0.011738:0.012950:0.005330
calcium-mimetic  radionuclide,  is  the  first :@0.084848:0.878616:0.481094:0.878616:0.481094:0.862860:0.084848:0.862860:0.012450:0.013143:0.003848:0.012450:0.003848:0.011699:0.018049:0.006388:0.018049:0.003848:0.018049:0.012508:0.006523:0.003848:0.012450:0.005330:0.004516:0.005792:0.013143:0.013181:0.003848:0.012604:0.011738:0.011699:0.012450:0.003848:0.003848:0.013181:0.012508:0.005330:0.005330:0.004505:0.003848:0.007466:0.005330:0.004514:0.006523:0.011738:0.012508:0.005330:0.004501:0.004686:0.004686:0.005792:0.007466:0.006523:0.005330
radionuclide for bone metastases therapy :@0.084848:0.895245:0.481101:0.895245:0.481101:0.879490:0.084848:0.879490:0.005792:0.013143:0.013181:0.003848:0.012604:0.011738:0.011699:0.012450:0.003848:0.003848:0.013181:0.012508:0.005184:0.006042:0.012604:0.005792:0.005180:0.013123:0.012604:0.011738:0.012508:0.005178:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.007466:0.012508:0.007466:0.005195:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
with  a  survival  benefit  when  used  in  the :@0.084848:0.911874:0.481094:0.911874:0.481094:0.896119:0.084848:0.896119:0.015990:0.003848:0.006523:0.011738:0.005330:0.003754:0.013143:0.005330:0.003758:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330:0.003772:0.013123:0.012508:0.011738:0.012508:0.004686:0.004686:0.006523:0.005330:0.003745:0.015990:0.011738:0.012508:0.011738:0.005330:0.003750:0.011699:0.007466:0.012508:0.013181:0.005330:0.003756:0.003848:0.011738:0.005330:0.003756:0.006523:0.011738:0.012508:0.005330
treatment of bone metastases. :@0.084848:0.928504:0.378135:0.928504:0.378135:0.912748:0.084848:0.912748:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.012604:0.006042:0.005330:0.013123:0.012604:0.011738:0.012508:0.005330:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.007466:0.012508:0.007466:0.005330:0.005330
Ra-223  dichloride adsorbs to the  hy-:@0.524249:0.096151:0.915160:0.096151:0.915160:0.080395:0.524249:0.080395:0.011680:0.013143:0.006388:0.010660:0.010660:0.010660:0.005330:0.011403:0.013181:0.003848:0.012450:0.011738:0.003848:0.012604:0.005792:0.003848:0.013181:0.012508:0.016722:0.013143:0.013181:0.007466:0.012604:0.005792:0.013123:0.007466:0.016722:0.006523:0.012604:0.016722:0.006523:0.011738:0.012508:0.005330:0.011382:0.011738:0.010314:0.006388
droxyapatite crystals of the bone matrix. It :@0.524249:0.112476:0.920498:0.112476:0.920498:0.096720:0.524249:0.096720:0.013181:0.005713:0.012604:0.009236:0.010314:0.013143:0.013123:0.013143:0.006523:0.003848:0.006523:0.012508:0.005311:0.012450:0.005792:0.010314:0.007466:0.006523:0.013143:0.003848:0.007466:0.005322:0.012604:0.006042:0.005311:0.006523:0.011738:0.012508:0.005311:0.013123:0.012604:0.011738:0.012508:0.005311:0.018049:0.013143:0.006523:0.005792:0.003848:0.009236:0.005330:0.005311:0.004349:0.006523:0.005330
is concentrated more at sites of increased :@0.524249:0.128800:0.920500:0.128800:0.920500:0.113045:0.524249:0.113045:0.003848:0.007466:0.005157:0.012450:0.012604:0.011738:0.012450:0.012498:0.011738:0.006523:0.005792:0.013143:0.006523:0.012508:0.013181:0.005142:0.018049:0.012604:0.005707:0.012508:0.005157:0.013143:0.006523:0.005157:0.007466:0.003848:0.006523:0.012508:0.007466:0.005157:0.012604:0.006042:0.005145:0.003848:0.011738:0.012450:0.005713:0.012508:0.013143:0.007466:0.012508:0.013181:0.005330
bone turnover – a feature characteristic of :@0.524249:0.145125:0.920507:0.145125:0.920507:0.129369:0.524249:0.129369:0.013123:0.012604:0.011738:0.012508:0.004333:0.006523:0.011699:0.006192:0.011738:0.012604:0.010660:0.012508:0.005792:0.004331:0.009621:0.004339:0.013143:0.004349:0.006042:0.012508:0.013143:0.006523:0.011699:0.005707:0.012508:0.004337:0.012450:0.011738:0.013143:0.005792:0.013143:0.012450:0.006523:0.012508:0.005792:0.003848:0.007466:0.006523:0.003848:0.012450:0.004337:0.012604:0.006042:0.005330
osteoblastic skeletal metastases. It there-:@0.524249:0.161450:0.915168:0.161450:0.915168:0.145694:0.524249:0.145694:0.012604:0.007466:0.006523:0.012508:0.012604:0.013123:0.003848:0.013143:0.007466:0.006523:0.003848:0.012450:0.008236:0.007466:0.009660:0.012508:0.003848:0.012508:0.006523:0.013143:0.003848:0.008236:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.007466:0.012508:0.007466:0.005330:0.008236:0.004349:0.006523:0.008236:0.006523:0.011738:0.012508:0.005705:0.012508:0.006388
fore concentrates more at sites of osteo-:@0.524249:0.177775:0.915158:0.177775:0.915158:0.162019:0.524249:0.162019:0.006042:0.012604:0.005707:0.012508:0.007591:0.012450:0.012604:0.011738:0.012450:0.012508:0.011738:0.006523:0.005792:0.013143:0.006523:0.012508:0.007466:0.007580:0.018049:0.012604:0.005707:0.012508:0.007589:0.013143:0.006523:0.007601:0.007466:0.003848:0.006523:0.012508:0.007466:0.007601:0.012604:0.006042:0.007587:0.012604:0.007466:0.006523:0.012508:0.012579:0.006388
blastic  skeletal metastases than normal :@0.524249:0.194100:0.920471:0.194100:0.920471:0.178344:0.524249:0.178344:0.013123:0.003848:0.013143:0.007466:0.006523:0.003848:0.012450:0.005330:0.006519:0.007466:0.009660:0.012508:0.003848:0.012508:0.006523:0.013143:0.003848:0.011834:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.007466:0.012508:0.007466:0.011834:0.006523:0.011738:0.013143:0.011738:0.011834:0.011738:0.012604:0.006317:0.018049:0.013143:0.003848:0.005330
bone. The emitted alpha particle causes :@0.524249:0.210424:0.920488:0.210424:0.920488:0.194668:0.524249:0.194668:0.013123:0.012604:0.011738:0.012508:0.005330:0.007812:0.008197:0.011738:0.012508:0.007812:0.012508:0.018049:0.003848:0.006523:0.006523:0.012508:0.013181:0.007812:0.013143:0.003848:0.013123:0.011738:0.013143:0.007812:0.013123:0.013143:0.005792:0.006523:0.003848:0.012450:0.003848:0.012508:0.007812:0.012450:0.013143:0.011699:0.007466:0.012508:0.007466:0.005330
double-stranded  DNA  damage  within  a :@0.524249:0.226749:0.920481:0.226749:0.920481:0.210993:0.524249:0.210993:0.013181:0.012604:0.011699:0.013123:0.003848:0.012508:0.006388:0.007466:0.006523:0.005792:0.013143:0.011738:0.013181:0.012508:0.013181:0.005330:0.005026:0.014316:0.014239:0.014239:0.005330:0.005020:0.013181:0.013143:0.018049:0.013143:0.012950:0.012508:0.005330:0.005024:0.015990:0.003848:0.006523:0.011738:0.003848:0.011738:0.005330:0.005030:0.013143:0.005330
radius of <0.1 mm (:@0.524249:0.243074:0.710157:0.243074:0.710157:0.227318:0.524249:0.227318:0.005792:0.013143:0.013181:0.003848:0.011699:0.007466:0.007658:0.012604:0.006042:0.007647:0.011661:0.010660:0.005330:0.010660:0.007658:0.018049:0.018049:0.007658:0.007100
versus:@0.710157:0.243074:0.765749:0.243074:0.765749:0.227318:0.710157:0.227318:0.010660:0.012508:0.005792:0.007466:0.011699:0.007466
 several mm for :@0.765749:0.243074:0.920515:0.243074:0.920515:0.227318:0.765749:0.227318:0.007658:0.007466:0.012508:0.010660:0.012508:0.005792:0.013143:0.003848:0.007658:0.018049:0.018049:0.007658:0.006042:0.012604:0.005792:0.005330
beta particles), hence has only minimal :@0.524249:0.259399:0.920450:0.259399:0.920450:0.243643:0.524249:0.243643:0.013123:0.012508:0.006523:0.013143:0.010025:0.013123:0.013143:0.005792:0.006523:0.003848:0.012450:0.003848:0.012508:0.007466:0.007100:0.005330:0.010025:0.011738:0.012508:0.011738:0.012450:0.012508:0.010025:0.011738:0.013143:0.007466:0.010025:0.012604:0.011738:0.003848:0.010314:0.010025:0.018049:0.003848:0.011738:0.003848:0.018049:0.013143:0.003848:0.005330
haematotoxicity.:@0.524249:0.275724:0.682633:0.275724:0.682633:0.259968:0.524249:0.259968:0.011738:0.013143:0.012508:0.018049:0.013143:0.006523:0.012604:0.006523:0.012604:0.009236:0.003848:0.012450:0.003848:0.006523:0.010314:0.005330
Radium-223 is indicated in metastatic :@0.542433:0.292048:0.920488:0.292048:0.920488:0.276292:0.542433:0.276292:0.011680:0.013143:0.013181:0.003848:0.011699:0.018049:0.006388:0.010660:0.010660:0.010660:0.011315:0.003848:0.007466:0.011315:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.011315:0.003848:0.011738:0.011315:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.005330
prostate-cancer patients with symptomat-:@0.524249:0.308373:0.915148:0.308373:0.915148:0.292617:0.524249:0.292617:0.013123:0.005715:0.012604:0.007466:0.006523:0.013143:0.006523:0.012508:0.006388:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.004551:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.004560:0.015990:0.003848:0.006523:0.011738:0.004560:0.007466:0.010314:0.018049:0.013123:0.006523:0.012604:0.018049:0.013143:0.006523:0.006388
ic bone metastases and no known visceral :@0.524249:0.324698:0.920481:0.324698:0.920481:0.308942:0.524249:0.308942:0.003848:0.012450:0.004330:0.013123:0.012604:0.011738:0.012508:0.004330:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.007466:0.012508:0.007466:0.004341:0.013143:0.011738:0.013181:0.004330:0.011738:0.012604:0.004330:0.009660:0.011738:0.012604:0.015990:0.011738:0.004330:0.010660:0.003848:0.007466:0.012450:0.012508:0.005792:0.013143:0.003848:0.005330
metastases.:@0.524249:0.341023:0.634373:0.341023:0.634373:0.325267:0.524249:0.325267:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.007466:0.012508:0.007466:0.005330
The  following  constitute  relative contra-:@0.524249:0.373659:0.915170:0.373659:0.915170:0.357903:0.524249:0.357903:0.008197:0.011738:0.012508:0.005330:0.006098:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.003848:0.011738:0.012950:0.005330:0.006102:0.012450:0.012604:0.011738:0.007466:0.006523:0.003848:0.006523:0.011699:0.006523:0.012508:0.005330:0.006096:0.005711:0.012508:0.003848:0.013143:0.006523:0.003848:0.010660:0.012508:0.011449:0.012450:0.012604:0.011738:0.006523:0.005792:0.013143:0.006388
indications to the use of Ra-223 for bone-:@0.524249:0.389984:0.915170:0.389984:0.915170:0.374228:0.524249:0.374228:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.006619:0.006523:0.012604:0.006619:0.006523:0.011738:0.012508:0.006610:0.011699:0.007466:0.012508:0.006619:0.012604:0.006042:0.006619:0.011680:0.013143:0.006388:0.010660:0.010660:0.010660:0.006631:0.006042:0.012604:0.005792:0.006610:0.013123:0.012604:0.011738:0.012508:0.006388
pain therapy::@0.524249:0.406309:0.649902:0.406309:0.649902:0.390553:0.524249:0.390553:0.013123:0.013143:0.003848:0.011738:0.005330:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
n   :@0.524242:0.419457:0.547050:0.419457:0.547050:0.411017:0.524242:0.411017:0.009762:0.003566:0.005914:0.003566
Karnofsky score <50% or ECOG :@0.543484:0.422577:0.835147:0.422577:0.835147:0.406821:0.543484:0.406821:0.011372:0.013143:0.006190:0.011738:0.012604:0.006042:0.007466:0.009660:0.010314:0.005330:0.007466:0.012450:0.012604:0.005707:0.012508:0.005330:0.011661:0.010660:0.010660:0.014913:0.005330:0.012604:0.005792:0.005330:0.010314:0.015644:0.016722:0.016779:0.005330
performance status >2:@0.543484:0.438901:0.754477:0.438901:0.754477:0.423145:0.543484:0.423145:0.013123:0.012508:0.006710:0.006042:0.012604:0.006317:0.018049:0.013143:0.011738:0.012450:0.012508:0.005330:0.007466:0.006523:0.013143:0.006523:0.011699:0.007466:0.005330:0.011661:0.010660
n   :@0.524242:0.452099:0.547050:0.452099:0.547050:0.443658:0.524242:0.443658:0.009762:0.003566:0.005914:0.003566
Limited bone-marrow reserve – :@0.543484:0.455218:0.836065:0.455218:0.836065:0.439462:0.543484:0.439462:0.008890:0.003848:0.018049:0.003848:0.006523:0.012508:0.013181:0.005330:0.013123:0.012604:0.011738:0.012508:0.006388:0.018049:0.013143:0.005792:0.005703:0.012604:0.015990:0.005330:0.005707:0.012508:0.007466:0.012508:0.005792:0.010660:0.012508:0.005330:0.009621:0.005330
absolute neutrophil count <1500/µL, :@0.543484:0.471543:0.882081:0.471543:0.882081:0.455787:0.543484:0.455787:0.013143:0.013123:0.007466:0.012604:0.003848:0.011699:0.006523:0.012508:0.005330:0.011738:0.012508:0.011699:0.006523:0.005703:0.012604:0.013123:0.011738:0.003848:0.003848:0.005330:0.012450:0.012604:0.011699:0.011738:0.006523:0.005330:0.011661:0.010660:0.010660:0.010660:0.010660:0.008409:0.011084:0.008890:0.005330:0.005330
platelets <100 000/µL and haemoglobin :@0.543484:0.487867:0.917845:0.487867:0.917845:0.472111:0.543484:0.472111:0.013123:0.003848:0.013143:0.006523:0.012508:0.003848:0.012508:0.006523:0.007466:0.005330:0.011661:0.010660:0.010660:0.010660:0.005330:0.010660:0.010660:0.010660:0.008409:0.011084:0.008890:0.005330:0.013143:0.011738:0.013181:0.005330:0.011738:0.013143:0.012508:0.018049:0.012604:0.012950:0.003848:0.012604:0.013123:0.003848:0.011738:0.005330
<10.0 g/dL:@0.543484:0.504192:0.641216:0.504192:0.641216:0.488436:0.543484:0.488436:0.011661:0.010660:0.010660:0.005330:0.010660:0.005330:0.012950:0.008409:0.013181:0.008890
n   :@0.524242:0.517381:0.547050:0.517381:0.547050:0.508941:0.524242:0.508941:0.009762:0.003566:0.005914:0.003566
Faecal incontinence:@0.543484:0.520500:0.736928:0.520500:0.736928:0.504744:0.543484:0.504744:0.009333:0.013143:0.012508:0.012450:0.013143:0.003848:0.005330:0.003848:0.011738:0.012450:0.012604:0.011738:0.006523:0.003848:0.011738:0.012508:0.011738:0.012450:0.012508
The following must be ensured before :@0.524242:0.553136:0.920474:0.553136:0.920474:0.537380:0.524242:0.537380:0.008197:0.011738:0.012508:0.013662:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.003848:0.011738:0.012950:0.013662:0.018049:0.011699:0.007466:0.006523:0.013662:0.013123:0.012508:0.013662:0.012508:0.011738:0.007466:0.011699:0.005713:0.012508:0.013181:0.013662:0.013123:0.012508:0.006042:0.012604:0.005709:0.012508:0.005330
a patient is considered for  Radium-223 :@0.524242:0.569461:0.920483:0.569461:0.920483:0.553705:0.524242:0.553705:0.013143:0.011892:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.011892:0.003848:0.007466:0.011892:0.012450:0.012604:0.011738:0.007466:0.003848:0.013181:0.012508:0.005713:0.012508:0.013181:0.011892:0.006042:0.012604:0.005792:0.005330:0.006546:0.011680:0.013143:0.013181:0.003848:0.011699:0.018049:0.006388:0.010660:0.010660:0.010660:0.005330
therapy::@0.524242:0.585786:0.602712:0.585786:0.602712:0.570030:0.524242:0.570030:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
n   :@0.524242:0.598984:0.547050:0.598984:0.547050:0.590543:0.524242:0.590543:0.009762:0.003566:0.005914:0.003566
Therapy indication and no contra-:@0.543484:0.602103:0.863582:0.602103:0.863582:0.586347:0.543484:0.586347:0.008197:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.013143:0.011738:0.013181:0.005330:0.011738:0.012604:0.005330:0.012450:0.012604:0.011738:0.006523:0.005792:0.013143:0.006388
indications are present:@0.543484:0.618427:0.755476:0.618427:0.755476:0.602672:0.543484:0.602672:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.013143:0.005717:0.012508:0.005330:0.013123:0.005711:0.012508:0.007466:0.012508:0.011738:0.006523
n   :@0.524242:0.631625:0.547050:0.631625:0.547050:0.623184:0.524242:0.623184:0.009762:0.003566:0.005914:0.003566
Exclusion of visceral metastases:@0.543484:0.634744:0.835834:0.634744:0.835834:0.618988:0.543484:0.618988:0.010314:0.009236:0.012450:0.003848:0.011699:0.007466:0.003848:0.012604:0.011738:0.005330:0.012604:0.006042:0.005330:0.010660:0.003848:0.007466:0.012450:0.012508:0.005792:0.013143:0.003848:0.005330:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.007466:0.012508:0.007466
n   :@0.524242:0.647945:0.547050:0.647945:0.547050:0.639505:0.524242:0.639505:0.009762:0.003566:0.005914:0.003566
Recent bone scan not older than :@0.543484:0.651064:0.859579:0.651064:0.859579:0.635308:0.543484:0.635308:0.011680:0.012508:0.012450:0.012508:0.011738:0.006523:0.005330:0.013123:0.012604:0.011738:0.012508:0.005330:0.007466:0.012450:0.013143:0.011738:0.005330:0.011738:0.012604:0.006523:0.005330:0.012604:0.003848:0.013181:0.012508:0.005792:0.005330:0.006523:0.011738:0.013143:0.011738:0.005330
three months showing increased tracer :@0.543484:0.667389:0.912307:0.667389:0.912307:0.651633:0.543484:0.651633:0.006523:0.011738:0.005707:0.012508:0.012508:0.005330:0.018049:0.012604:0.011738:0.006523:0.011738:0.007466:0.005330:0.007466:0.011738:0.012604:0.015990:0.003848:0.011738:0.012950:0.005330:0.003848:0.011738:0.012450:0.005688:0.012508:0.013143:0.007466:0.012508:0.013181:0.005330:0.006523:0.005792:0.013143:0.012450:0.012508:0.005792:0.005330
uptake at sites corresponding to region :@0.543484:0.683714:0.913770:0.683714:0.913770:0.667958:0.543484:0.667958:0.011699:0.013123:0.006523:0.013143:0.009660:0.012508:0.005330:0.013143:0.006523:0.005330:0.007466:0.003848:0.006523:0.012508:0.007466:0.005330:0.012450:0.012604:0.005792:0.005700:0.012508:0.007466:0.013123:0.012604:0.011738:0.013181:0.003848:0.011738:0.012950:0.005330:0.006523:0.012604:0.005330:0.005696:0.012508:0.012950:0.003848:0.012604:0.011738:0.005330
of bone pain:@0.543484:0.700039:0.664615:0.700039:0.664615:0.684283:0.543484:0.684283:0.012604:0.006042:0.005330:0.013123:0.012604:0.011738:0.012508:0.005330:0.013123:0.013143:0.003848:0.011738
n   :@0.524242:0.713227:0.547050:0.713227:0.547050:0.704787:0.524242:0.704787:0.009762:0.003566:0.005914:0.003566
Recent blood count not older than  :@0.543484:0.716347:0.880457:0.716347:0.880457:0.700591:0.543484:0.700591:0.011680:0.012508:0.012450:0.012508:0.011738:0.006523:0.005330:0.013123:0.003848:0.012604:0.012604:0.013181:0.005330:0.012450:0.012604:0.011699:0.011738:0.006523:0.005330:0.011738:0.012604:0.006523:0.005330:0.012604:0.003848:0.013181:0.012508:0.005792:0.005330:0.006523:0.011738:0.013143:0.011738:0.005272:0.005330
10 days.:@0.543484:0.732671:0.619569:0.732671:0.619569:0.716915:0.543484:0.716915:0.010660:0.010660:0.005330:0.013181:0.013143:0.010314:0.007466:0.005330
The treatment is usually performed on an :@0.524242:0.765308:0.920479:0.765308:0.920479:0.749552:0.524242:0.749552:0.008197:0.011738:0.012508:0.006933:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.006931:0.003848:0.007466:0.006947:0.011699:0.007466:0.011699:0.013143:0.003848:0.003848:0.010314:0.006947:0.013123:0.012508:0.006710:0.006042:0.012604:0.006323:0.018049:0.012508:0.013181:0.006947:0.012604:0.011738:0.006935:0.013143:0.011738:0.005330
outpatient basis. Hospitalisation should be :@0.524242:0.781632:0.920470:0.781632:0.920470:0.765877:0.524242:0.765877:0.012604:0.011699:0.006523:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.005802:0.013123:0.013143:0.007466:0.003848:0.007466:0.005330:0.005811:0.013143:0.012604:0.007466:0.013123:0.003848:0.006523:0.013143:0.003848:0.003848:0.007466:0.013143:0.006523:0.003848:0.012621:0.011738:0.005811:0.007466:0.011738:0.012604:0.011699:0.003848:0.013181:0.005811:0.013123:0.012508:0.005330
considered in patients with faecal incon-:@0.524242:0.797957:0.915128:0.797957:0.915128:0.782201:0.524242:0.782201:0.012450:0.012604:0.011738:0.007466:0.003848:0.013181:0.012508:0.005711:0.012508:0.013181:0.007447:0.003848:0.011738:0.007447:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.007447:0.015990:0.003848:0.006523:0.011738:0.007447:0.006042:0.013143:0.012508:0.012450:0.013143:0.003848:0.007447:0.003848:0.011738:0.012450:0.012604:0.011738:0.006388
tinence or those with severe debilitation.:@0.524242:0.814282:0.900935:0.814282:0.900935:0.798526:0.524242:0.798526:0.006523:0.003848:0.011738:0.012508:0.011738:0.012450:0.012508:0.005330:0.012604:0.005792:0.005330:0.006523:0.011738:0.012604:0.007466:0.012508:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330:0.007466:0.012508:0.010660:0.012508:0.005680:0.012508:0.005330:0.013181:0.012508:0.013123:0.003848:0.003848:0.003848:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330
The  ALSYMPCA  trial was a phase III, :@0.542426:0.830607:0.920508:0.830607:0.920508:0.814851:0.542426:0.814851:0.008197:0.011738:0.012508:0.005330:0.007658:0.014239:0.008890:0.009583:0.011392:0.017684:0.011392:0.015644:0.014220:0.005330:0.007666:0.006523:0.005792:0.003848:0.013143:0.003848:0.013008:0.015990:0.013143:0.007466:0.013008:0.013143:0.013008:0.013123:0.011738:0.013143:0.007466:0.012508:0.013008:0.004349:0.004349:0.004349:0.005330:0.005330
randomised, double-blind, placebo-con-:@0.524242:0.846932:0.915151:0.846932:0.915151:0.831176:0.524242:0.831176:0.005792:0.013143:0.011738:0.013181:0.012604:0.018049:0.003848:0.007466:0.012508:0.013181:0.005330:0.009640:0.013181:0.012604:0.011699:0.013123:0.003848:0.012508:0.006388:0.013123:0.003848:0.003848:0.011738:0.013181:0.005330:0.009640:0.013123:0.003848:0.013143:0.012450:0.012508:0.013123:0.012604:0.006388:0.012450:0.012604:0.011738:0.006388
trolled study that randomly assigned 921 :@0.524242:0.863256:0.920476:0.863256:0.920476:0.847500:0.524242:0.847500:0.006523:0.005709:0.012604:0.003848:0.003848:0.012508:0.013181:0.008524:0.007466:0.006523:0.011699:0.013181:0.010314:0.008524:0.006523:0.011738:0.013143:0.006523:0.008524:0.005792:0.013143:0.011738:0.013181:0.012604:0.018049:0.003848:0.010314:0.008524:0.013143:0.007466:0.007466:0.003848:0.012950:0.011738:0.012508:0.013181:0.008524:0.010660:0.010660:0.010660:0.005330
patients in a 2:1 ratio to receive six injec-:@0.524242:0.879581:0.915149:0.879581:0.915149:0.863825:0.524242:0.863825:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.007254:0.003848:0.011738:0.007254:0.013143:0.007254:0.010660:0.005330:0.010660:0.007254:0.005792:0.013143:0.006523:0.003848:0.012604:0.007254:0.006523:0.012604:0.007254:0.005713:0.012508:0.012450:0.012508:0.003848:0.010660:0.012508:0.007254:0.007466:0.003848:0.009236:0.007254:0.003848:0.011738:0.003906:0.012508:0.012450:0.006388
tions of Radium-223 or matching placebo. :@0.524242:0.895906:0.920476:0.895906:0.920476:0.880150:0.524242:0.880150:0.006523:0.003848:0.012604:0.011738:0.007466:0.005028:0.012604:0.006042:0.005026:0.011680:0.013143:0.013181:0.003848:0.011699:0.018049:0.006388:0.010660:0.010660:0.010660:0.005042:0.012604:0.005792:0.005024:0.018049:0.013143:0.006523:0.012450:0.011738:0.003848:0.011738:0.012950:0.005024:0.013123:0.003848:0.013143:0.012450:0.012508:0.013123:0.012604:0.005330:0.005330
There  was  a  14.9  months  survival  benefit :@0.524242:0.912231:0.920487:0.912231:0.920487:0.896475:0.524242:0.896475:0.008197:0.011738:0.012508:0.005703:0.012508:0.005330:0.003365:0.015990:0.013143:0.007466:0.005330:0.003373:0.013143:0.005330:0.003367:0.010660:0.010660:0.005330:0.010660:0.005330:0.003373:0.018049:0.012604:0.011738:0.006523:0.011738:0.007466:0.005330:0.003358:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330:0.003385:0.013123:0.012508:0.011738:0.012508:0.004686:0.004686:0.006523:0.005330
in the  Radium-223  group,  compared to  :@0.524242:0.928556:0.920481:0.928556:0.920481:0.912800:0.524242:0.912800:0.003848:0.011738:0.010660:0.006523:0.011738:0.012508:0.005330:0.005317:0.011680:0.013143:0.013181:0.003848:0.011699:0.018049:0.006388:0.010660:0.010660:0.010660:0.005330:0.005342:0.012950:0.005709:0.012604:0.011699:0.013123:0.005330:0.005330:0.005319:0.012450:0.012604:0.018049:0.013123:0.013143:0.005713:0.012508:0.013181:0.010660:0.006523:0.012604:0.000000:0.005330
Figure 2. Excellent response to therapy :@0.084841:0.096970:0.419446:0.096970:0.419446:0.080579:0.084841:0.080579:0.009756:0.005272:0.011257:0.011218:0.007158:0.010160:0.003887:0.010680:0.005003:0.003887:0.010275:0.009563:0.008467:0.010160:0.005292:0.005292:0.010160:0.011159:0.007062:0.003887:0.007158:0.010160:0.008351:0.011565:0.011103:0.011276:0.008351:0.010160:0.003887:0.006966:0.011103:0.003887:0.007062:0.011276:0.010160:0.007100:0.010160:0.011334:0.010064:0.003887
after two cycles of  Ac-PSMA-617. This :@0.084841:0.112409:0.425180:0.112364:0.425180:0.095973:0.084841:0.096018:0.010160:0.006850:0.006966:0.010160:0.007312:0.003887:0.007158:0.014314:0.011103:0.003887:0.008967:0.009775:0.008678:0.005292:0.010160:0.008351:0.003887:0.011103:0.006562:0.003887:0.018684:0.012354:0.008909:0.006196:0.011180:0.010391:0.016221:0.012469:0.006196:0.010680:0.010680:0.010680:0.005003:0.003137:0.010314:0.011276:0.005272:0.008351:0.893654
225:@0.243307:0.106579:0.261986:0.106579:0.261986:0.097024:0.243307:0.097024:0.006226:0.006226:0.006226
impressive response in a patient with :@0.084840:0.127802:0.406126:0.127802:0.406126:0.111411:0.084840:0.111411:0.005272:0.016548:0.011507:0.007158:0.010160:0.008351:0.008351:0.005272:0.009908:0.010160:0.003887:0.007158:0.010160:0.008351:0.011565:0.011103:0.011276:0.008351:0.010160:0.003887:0.005272:0.011276:0.003887:0.010160:0.003887:0.011507:0.010004:0.007062:0.005272:0.010160:0.011161:0.007062:0.003887:0.014605:0.005272:0.007062:0.011276:0.003887
metastatic castration-resistant prostate :@0.084840:0.143241:0.426254:0.143241:0.426254:0.126850:0.084840:0.126850:0.016548:0.010160:0.007062:0.010160:0.008351:0.007062:0.010006:0.007062:0.005272:0.008678:0.003887:0.008753:0.010160:0.008351:0.007062:0.007100:0.010006:0.007062:0.005272:0.011103:0.011276:0.006196:0.007156:0.010160:0.008351:0.005272:0.008351:0.007062:0.010160:0.011161:0.007062:0.003887:0.011507:0.007158:0.011103:0.008351:0.007062:0.010006:0.006966:0.010160:0.003887
cancer was demonstrated by  Ga-PSMA-11 :@0.084840:0.158679:0.456362:0.158666:0.456362:0.142275:0.084840:0.142288:0.008755:0.010160:0.011276:0.008467:0.010160:0.007312:0.003887:0.014470:0.010160:0.008351:0.003887:0.011468:0.010160:0.016548:0.011103:0.011276:0.008351:0.007062:0.007099:0.010006:0.006966:0.010160:0.011468:0.003887:0.011334:0.010064:0.003887:0.012461:0.013277:0.010160:0.006196:0.011180:0.010391:0.016221:0.012469:0.006196:0.010680:0.010680:0.795124
68:@0.332573:0.152882:0.345026:0.152882:0.345026:0.143326:0.332573:0.143326:0.006226:0.006226
PET/CT images of before (top panel) and after :@0.084849:0.174104:0.477003:0.174104:0.477003:0.157714:0.084849:0.157714:0.011180:0.010372:0.010545:0.006369:0.011717:0.010545:0.003887:0.005272:0.016548:0.010160:0.011257:0.010160:0.008351:0.003887:0.011103:0.006562:0.003887:0.011563:0.010160:0.006369:0.011103:0.007158:0.010160:0.003887:0.006042:0.006966:0.011103:0.011507:0.003887:0.011507:0.010160:0.011276:0.010160:0.005292:0.006042:0.003887:0.010160:0.011276:0.011468:0.003887:0.010160:0.006848:0.006966:0.010160:0.007312:0.003887
(bottom panel):@0.084849:0.189543:0.213561:0.189543:0.213561:0.173152:0.084849:0.173152:0.006042:0.011565:0.011103:0.007062:0.006966:0.011103:0.016548:0.003887:0.011507:0.010160:0.011276:0.010160:0.005292:0.006042
   :@0.477531:0.502910:0.482919:0.502910:0.482919:0.486877:0.477531:0.486877:0.005388:-0.005388:0.005388